Phathom Pharmaceuticals, Inc. (PHAT)
Healthcare
- Fundamental
- 3
- Sentiment
- 2
- Technical
- 2
Do Nothing: qualitativeScore is 2 (below required floor of 3); strategy requires qualitativeScore >= 3 before any bullish entry, and PHAT remains in a post-earnings downtrend below key daily averages.
Company overview
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for gastrointestinal disorders. Its key product, vonoprazan, is a potassium-competitive acid blocker undergoing Phase III trials for GERD and H. pylori infection. The company operates in the U.S., Europe, and Canada.
Fundamental
fairPhathom is showing revenue growth and reduced losses, but remains unprofitable with balance-sheet risks.
PHAT is scaling VOQUEZNA revenue rapidly and losses are shrinking (per the latest 10-Q, first-half net loss improved materially YoY) with $182.5M cash at 2026-06-30 and management stating there is no substantial doubt about going concern. The offsets are still-negative profitability/cash generation and a financing-heavy balance sheet (negative equity and a distressed Altman Z-Score). Overall: improving but higher-risk fundamentals (fundamentalScore 3/5).
Sentiment
weakSentiment is negative with litigation noise and no immediate catalysts.
The 2026-07-30 Q2 results/business update (announced) has been digested negatively in third-party coverage (guidance-reset narrative and sharp same-day drop), pulling media sentiment down vs the prior 1–3 months. No regulator-confirmed legal actions surfaced, but a cluster of plaintiff-law-firm 'investigation' notices adds low-confidence headline risk.
Technical
weakThe stock is in a bearish trend with no bullish triggers active.
Trend and momentum remain bearish despite an oversold reading: at the latest close PHAT sat below the SMA20/50/200, EMA9/21, WMA9/21, DEMA14, and daily VWAP, while MACD stayed below both its signal and zero. RSI14 at 33.04 and Williams %R at -92.98 show downside exhaustion, but ADX14 at 28.23 says the prevailing move is still a strong downtrend rather than a confirmed bullish reversal.
You’re looking at 2026-08-07 — about 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.